The Indian Pharma Market (IPM) clocked Rs 6227 crores in January 2014 and has grown at 8.5 per cent. January 2013 growth driver split shows positive on the parameter of volume and new introductions leading to overall positive growths. For January 2014, amongst the top 10 corporates, Emcure has seen a growth of 20.9 per cent followed by Sun Pharma at 20.1 per cent and Lupin at 15.4 per cent.
32 corporates have crossed the growth of IPM in January 2014 amongst top 50 corporates. Biocon has the highest growth of 41.2 per cent followed by Ajanta at 36.1 per cent and Allergan at 35.7 per cent. Amongst the 11-20 ranked companies, Aristo has shown a high growth at 21.8 per cent followed by Macleods at 20.9 per cent and Torrent at 15.8 per cent. Serum Institute has entered the Rs 100-crore club and Glenmark into the Rs 1600-crore club. Ajanta Pharma has moved into the top 50.
|
With Bonus Units at Full Value (Val in Crs)
|
||||||||
|
Val in Crs
|
Rank
|
MAT Jan -14
|
Jan-14
|
|||||
|
COMPANY
|
MAT
|
MTH
|
Val (Cr)
|
MS%
|
GR%
|
Val (Cr)
|
MS%
|
GR%
|
| IPM |
74490
|
100.00
|
5.9
|
6227
|
100.00
|
8.5
|
||
| Sun Pharma |
1
|
1
|
3985
|
5.35
|
17.2
|
377
|
6.06
|
20.1
|
| Cipla |
2
|
2
|
3725
|
5.00
|
5.8
|
329
|
5.28
|
3.8
|
| Zydus Cadila |
3
|
3
|
2968
|
3.98
|
9.6
|
256
|
4.11
|
13.3
|
| Ranbaxy |
4
|
5
|
2886
|
3.87
|
-0.2
|
223
|
3.58
|
-3.6
|
| Glaxo |
5
|
7
|
2829
|
3.80
|
-12.9
|
215
|
3.45
|
-12.7
|
| Abbott HC |
6
|
6
|
2721
|
3.65
|
2.3
|
217
|
3.48
|
0.9
|
| Mankind |
7
|
8
|
2677
|
3.59
|
6.5
|
214
|
3.44
|
9.3
|
| Lupin |
8
|
4
|
2495
|
3.35
|
12.0
|
225
|
3.61
|
15.4
|
| Alkem |
9
|
9
|
2328
|
3.13
|
9.9
|
185
|
2.98
|
11.4
|
| Sanofi-Aventis |
10
|
11
|
1930
|
2.59
|
3.8
|
161
|
2.58
|
5.6
|
| Macleods |
11
|
10
|
1930
|
2.59
|
7.9
|
171
|
2.75
|
20.9
|
| Intas |
12
|
12
|
1889
|
2.54
|
11.5
|
161
|
2.58
|
5.1
|
| Aristo |
13
|
13
|
1787
|
2.40
|
10.5
|
145
|
2.33
|
21.8
|
| Pfizer |
14
|
16
|
1618
|
2.17
|
-3.5
|
131
|
2.10
|
-3.2
|
| Glenmark |
15
|
14
|
1607
|
2.16
|
16.9
|
143
|
2.29
|
15.6
|
| Dr. Reddys |
16
|
15
|
1601
|
2.15
|
5.7
|
133
|
2.13
|
5.4
|
| Micro Lab |
17
|
18
|
1510
|
2.03
|
8.6
|
122
|
1.96
|
14.9
|
Indian companies have grown at 11.4 per cent versus one per cent for MNCs in January 2014. Amongst the top 50 in MNCs, Allergan grew the highest at 35.7 per cent, followed by MSD at 17per cent and Merck at 15 per cent. The DPCO 2013 containing molecules market was at –10.5 per cent whereas the non- DPCO market grew by 11.7 per cent resulting in an overall growth of 8.5 per cent.
The DPCO 2013 portfolio for GSK de-grew at 28.4 per cent and Ranbaxy de-grew by 24.7 per cent, whereas Sun Pharma had the least impact with its DPCO 2013 portfolio de-growing at 4.2 per cent.
| SUPERGROUP | MAT VAL IN CRS | MAT VAL GR | JAN-14 MONTH | JAN-14 MONTH GR |
| IPM |
74452.2
|
5.8
|
6232.6
|
8.6
|
| ANTI-INFECTIVES |
12559.5
|
0.6
|
964.9
|
1.3
|
| CARDIAC |
9240.4
|
8.6
|
823.2
|
8.8
|
| GASTRO INTESTINAL |
8406.9
|
5.4
|
674.3
|
9.9
|
| VITAMINS / MINERALS / NUTRIENTS |
6592.8
|
4.8
|
531.2
|
10.9
|
| RESPIRATORY |
5848.1
|
9.1
|
543.7
|
9.8
|
| PAIN / ANALGESICS |
5363.6
|
3.7
|
428.7
|
5.8
|
| ANTI DIABETIC |
5209.1
|
14.8
|
481.5
|
19.1
|
| NEURO / CNS |
4674.1
|
8.1
|
410.4
|
8.5
|
| GYNAECOLOGICAL |
4653.3
|
2.2
|
383.9
|
1.8
|
| DERMA |
4068.8
|
10.4
|
350.3
|
16.0
|
| OPHTHAL / OTOLOGICALS |
1352.0
|
9.0
|
110.8
|
12.4
|
| HORMONES |
1257.4
|
5.4
|
106.2
|
7.5
|
| VACCINES |
1087.3
|
-4.3
|
85.7
|
-3.3
|
| ANTI-NEOPLASTICS |
977.5
|
21.1
|
85.2
|
37.0
|
| OTHERS |
912.6
|
1.9
|
82.2
|
18.3
|
| BLOOD RELATED |
882.5
|
2.1
|
72.1
|
9.2
|
| ANTI MALARIALS |
611.8
|
0.9
|
31.2
|
10.0
|
| SEX STIMULANTS / REJUVENATORS |
420.2
|
5.1
|
39.0
|
8.6
|
| STOMATOLOGICALS |
334.1
|
7.5
|
28.0
|
9.7
|
From therapy perspective, 13 therapies have outgrown the IPM growth and nine therapies have double digit growths. The respiratory market grew at 9.8 per cent, gastrointestinal market grew at 10 per cent whereas anti-infectives grew at 0.6 per cent. The anti-diabetic market grew at 17.5 per cent and cardiac at nine per cent in chronic business. Opthal/ Otologicals market grew by 18 per cent, whereas the derma market was at 16 per cent. From regional perspective, 12 regions have outgrown the IPM growth. Vidarbha market grew the highest at 18.1 per cent. No region had negative growths in January 2014 after three months. The biggest molecule Amoxycillin + Clavulanic de-grew by 0.3 per cent, whereas Cefixime de-grew at 2.6 per cent. Paracetamol grew at 10.5 per cent and Azithromycin de-grew by -1.4 per cent. The markets of Vitamin- D grew by 42.1 per cent, Glimepiride + Metformin grew at 35.2 per cent, Telmisartan by 22.4 per cent, Levocetirizine + Montelukast by 20.5 per cent and Rosuvastain by 20 per cent.
A total of 83 brands were launched in January 2014. Gerbisa and Hyocimax are the top NIs for the month from Zydus.
About PharmaTrac
PharmaTrac is a the secondary sales data audit conducted by AIOCD Pharmasofttech AWACS, a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors (AIOCD ) in a joint venture with Trikaal Mediinfotech. AWACS (Advanced Working, Action & Correction System) reflects the underlying philosophy behind AIOCD AWACS’ research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information.
Terminologies used
MAT – Moving Annual Total
MTH – Month
Val (Cr) – Value in Crores
MS per cent – Market Share in Percentage
GR per cent – Growth in percentage.
For more information, visit http://www.aiocd.net